News25/Ratings0
News · 26 weeks310%
2025-10-262026-04-19
Mix1290d
- Other6(50%)
- SEC Filings6(50%)
Latest news
25 items- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECSEC Form 8-K filed by Lisata Therapeutics Inc.8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECSEC Form 10-K filed by Lisata Therapeutics Inc.10-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stockholders tender their shares Transaction expected to close in the second quarter of 2026 BASKING RIDGE, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a definitive agreement to be acquired by Kuva La
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu"). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender OfferStockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. ("Kuva"), a privately-held company. Pursuant to the terms and conditions of the term
- INSIDERPresident & CEO Mazzo David J was granted 81,000 shares and covered exercise/tax liability with 41,096 shares, increasing direct ownership by 15% to 311,890 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSVP, Fin/Treas, Chief Actg Off Nisco James was granted 15,000 shares and covered exercise/tax liability with 6,180 shares, increasing direct ownership by 38% to 32,311 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSVP, Bus Dev, General Counsel Imam Tariq covered exercise/tax liability with 3,501 shares and was granted 15,000 shares, increasing direct ownership by 47% to 36,078 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDEREVP, R&D and CMO Buck Kristen K was granted 25,000 shares and covered exercise/tax liability with 11,332 shares, increasing direct ownership by 17% to 93,462 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERDirector Henson Heidi was granted 30,456 shares, increasing direct ownership by 55% to 85,725 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERDirector Klosk Steven M was granted 30,456 shares, increasing direct ownership by 47% to 95,815 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERDirector Flowers Cynthia Louise was granted 30,456 shares, increasing direct ownership by 47% to 95,446 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERDirector Brown Gregory B was granted 30,456 shares, increasing direct ownership by 47% to 95,659 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERDirector Azab Mohammad was granted 30,456 shares, increasing direct ownership by 41% to 104,925 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- SECSEC Form S-8 filed by Lisata Therapeutics Inc.S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)